| 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE
VACCINE |
- Prevenar 13®
- Pneumovax 23®
|
- Pfizer Australia Pty Ltd
- Seqiris (Australia) Pty Ltd
|
Pneumococcal disease |
Jul 2019 |
|
| 21-VALENT PNEUMOCOCCAL CONJUGATE VACCINE |
Capvaxive® |
MERCK SHARP & DOHME (AUSTRALIA) PTY LTD |
Prevention of pneumococcal disease in adults |
Nov 2025 |
|
| ABACAVIR SULFATE WITH LAMIVUDINE |
Kivexa® |
GlaxoSmithKline Australia |
Human Immunodeficiency Virus (HIV) |
Jul 2005 |
n/a |
| ABALOPARATIDE |
Eladynos® |
THERAMEX AUSTRALIA PTY LTD |
Osteoporosis |
Jul 2025 |
|
| ABATACEPT |
Orencia® |
Bristol-Myers Squibb Australia Pty Ltd |
|
Nov 2007 |
|
| ABATACEPT |
Orencia® |
Bristol-Myers Squibb Australia Pty Ltd |
|
Jul 2011 |
|
| ABATACEPT |
Orencia® |
Bristol-Myers Squibb Australia Pty Ltd |
|
Nov 2015 |
|
| ABATACEPT |
Orencia® |
Bristol-Myers Squibb Australia Pty Ltd |
|
Mar 2018 |
|
| ABEMACICLIB |
Verzenio® |
Eli Lilly Australia Pty Ltd |
Breast cancer |
Mar 2022 |
|
| ABEMACICLIB |
Verzenio® |
Eli Lilly Australia Pty Ltd |
Breast cancer |
Mar 2021 |
|
| ABEMACICLIB |
Verzenio® |
Eli Lilly Australia Pty Ltd |
|
Mar 2019 |
|
| ABEMACICLIB |
Verzenio® |
Eli Lilly Australia Pty Ltd |
Hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative
(HER2-) breast cancer |
Nov 2023 |
|
| ABEMACICLIB |
Verzenio® |
Eli Lilly Australia Pty Ltd |
Breast cancer |
Mar 2023 |
|
| ABIRATERONE |
Zytiga® |
Janssen-Cilag Pty Ltd |
|
Jul 2017 |
|
| ABIRATERONE |
Zytiga® |
Janssen-Cilag Pty Ltd |
|
Mar 2017 |
|
| ABIRATERONE |
Zytiga® |
Janssen-Cilag Pty Ltd |
Castration resistant carcinoma of the prostate |
Jul 2021 |
|
| ABIRATERONE |
Zytiga® |
Janssen-Cilag Pty Ltd |
|
Nov 2011 |
|
| ABIRATERONE |
Zytiga® |
Janssen-Cilag Pty Ltd |
|
Nov 2012 |
|
| ABIRATERONE |
Zytiga® |
Janssen-Cilag Pty Ltd |
|
Mar 2012 |
|
| ABIRATERONE |
Zytiga® |
Janssen-Cilag Pty Ltd |
|
Jul 2012 |
|
| ABIRATERONE ACETATE AND PREDNISOLONE |
Andriga-10 |
ACTOR PHARMACEUTICALS PTY LTD |
Castration resistant carcinoma of the prostate |
Jul 2025 |
|
| ABIRATERONE ACETATE |
Zytiga® |
Janssen-Cilag Pty Ltd |
Metastatic prostate cancer |
Mar 2021 |
|
| ABIRATERONE ACETATE |
Zytiga® |
Janssen-Cilag Pty Ltd |
|
Jul 2014 |
|
| ABIRATERONE AND METHYLPREDNISOLONE |
Yonsa Mpred® |
Sun Pharma ANZ Pty Ltd |
Prostate cancer |
Nov 2022 |
|
| ABIRATERONE AND METHYLPREDNISOLONE |
Yonsa Mpred® |
Sun Pharma ANZ Pty Ltd |
Prostate cancer |
Mar 2022 |
|
| ABIRATERONE AND METHYLPREDNISOLONE |
Yonsa Mpred® |
Sun Pharma ANZ Pty Ltd |
Metastatic hormone sensitive prostate cancer |
Jul 2023 |
|
| ABROCITINIB |
Cibinqo® |
PFIZER AUSTRALIA PTY LTD |
Severe atopic dermatitis |
Nov 2024 |
|
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia or small lymphocytic lymphoma |
Dec 2022 |
|
| ACALABRUTINIB |
Calquence® |
ASTRAZENECA PTY LTD |
Mantle cell lymphoma |
Jul 2025 |
|
| ACALABRUTINIB |
Calquence® |
ASTRAZENECA PTY LTD |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Nov 2025 |
|
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Relapsed and/or refractory mantle cell lymphoma (R/R MCL) |
Jul 2021 |
|
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Nov 2021 |
|
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia or small lymphocytic lymphoma. |
Mar 2023 |
|
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Jul 2023 |
|
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Mar 2020 |
|
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Jul 2020 |
|
| ACICLOVIR |
Xorox® |
Clinect Pty Ltd |
Herpes simplex keratitis |
Mar 2021 |
|
| ACICLOVIR |
Acivision® |
Medsurge Healthcare Pty Ltd |
Herpes simplex keratitis |
Jul 2015 |
|
| ACLIDINIUM BROMIDE |
Bretaris® Genuair® |
A.Menarini Australia Pty Limited |
|
Mar 2014 |
|
| ACLIDINIUM BROMIDE WITH EFORMOTEROL FUMARATE DEHYDRATE |
Brimica® Genuair® |
A.Menarini Australia Pty Limited |
|
Jul 2015 |
|
| ADALIMUMAB |
Humira® |
Abbott Australasia Pty Ltd |
|
Mar 2009 |
|
| ADALIMUMAB |
Yuflyma® |
Celltrion Healthcare Australia Pty Ltd |
Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile
idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid
arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque
psoriasis Moderate to severe hidradenitis suppurativa |
Jul 2022 |
|
| ADALIMUMAB |
Humira® |
Abbott Australasia Pty Ltd |
|
Mar 2010 |
|
| ADALIMUMAB |
Humira® |
Abbott Australasia Pty Ltd |
|
Nov 2010 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Jul 2017 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Mar 2017 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Dec 2017 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Immune-mediated inflammatory disease |
Jul 2025 |
|
| ADALIMUMAB |
Abrilada® |
Pfizer Australia Pty Ltd |
Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile
idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active
rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic
plaque psoriasis; Moderate to severe hidradenitis suppurativa. |
Jul 2021 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Severe Crohn disease; Moderate to severe ulcerative colitis. |
Nov 2021 |
|
| ADALIMUMAB |
Hulio® |
Alphapharm Pty Ltd |
Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile
idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active
rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic
plaque psoriasis; Moderate to severe hidradenitis suppurativa. |
Nov 2021 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Nov 2013 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Mar 2013 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Moderate to severe hidradenitis suppurativa |
Nov 2019 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Nov 2014 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Jul 2014 |
|
| ADALIMUMAB |
|
Abbott Australasia Pty Ltd |
|
Nov 2007 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Nov 2016 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Mar 2016 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Mar 2016 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Jul 2016 |
|
| ADALIMUMAB |
Hyrimoz® |
SANDOZ PTY LTD |
Severe Crohn disease (CD) Moderate to severe ulcerative colitis (UC) Severe active
juvenile idiopathic arthritis (JIA) Complex refractory fistulising Crohn disease (CD)
Severe active rheumatoid arthritis (RA) Severe psoriatic arthritis (PsA) Ankylosing
spondylitis (AS) Severe chronic plaque psoriasis (CPP) Moderate to severe hidradenitis
suppurativa (HS) |
Jul 2024 |
|
| ADALIMUMAB |
Yuflyma® |
Celltrion Healthcare Australia Pty Ltd |
Complex refractory fistulising Crohn disease Ulcerative colitis Crohn disease Chronic
plaque psoriasis Hidradenitis suppurativa |
Mar 2024 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Vision threatening non-infectious uveitis |
Mar 2024 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Immune-mediated inflammatory disease |
Mar 2024 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
Immune-mediated inflammatory disease (IMID) |
Dec 2024 |
|
| ADALIMUMAB |
Hadlima® |
Organon Pharma Pty Ltd |
Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile
idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid
arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque
psoriasis Moderate to severe hidradenitis suppurativa |
Nov 2023 |
|
| ADALIMUMAB |
Ardalicip® |
Cipla Australia Pty Ltd |
Severe Crohn disease; moderate to severe ulcerative colitis; Severe active juvenile
idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active
rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic
plaque psoriasis; Moderate to severe hidradenitis suppurativa |
Jul 2023 |
|
| ADALIMUMAB |
Humira® |
Abbott Australasia Pty Ltd |
|
Jul 2008 |
|
| ADALIMUMAB |
Humira® |
Abbott Australasia Pty Ltd |
|
Nov 2006 |
|
| ADALIMUMAB |
Humira® |
Abbott Australasia Pty Ltd |
|
Mar 2006 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Nov 2015 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Jul 2015 |
|
| ADALIMUMAB |
Idacio® |
Fresenius Kabi Australia Pty Limited |
Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile
idiopathic arthritis; Complex refractory Fistulising Crohn disease; Severe active
rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic
plaque psoriasis; Moderate to severe hidradenitis suppurativa |
Nov 2020 |
|
| ADALIMUMAB |
Hadlima® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Severe Crohn disease; complex refractory fistulising Crohn disease; moderate to severe
ulcerative colitis; severe active juvenile idiopathic arthritis; adult patients with
a history of jovenile idiopathic arthritis; severe psoriatic arthritis; ankylosing
spondylitis; severe chronic plaque psoriasis; severe active rheumatoid arthritis |
Nov 2020 |
|
| ADALIMUMAB |
Hyrimoz® |
Sandoz Pty Ltd |
Crohn disease; Ulcerative colitis; Juvenile idiopathic arthritis; Fistulising Crohn
disease; Rheumatoid arthritis; Psoriatic arthritis; Ankylosing spondylitis; Chronic
plaque psoriasis; Hidradenitis suppurativa |
Mar 2020 |
|
| ADALIMUMAB |
Hadlima® |
Merck Sharp & Dohme (Australia) Pty Ltd |
Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis;
Severe chronic plaque psoriasis; Juvenile idiopathic arthritis; Severe crohn’s disease;
Refractory fistulising crohn’s disease; moderate to severe hidradenitis suppurativa |
Jul 2020 |
|
| ADALIMUMAB |
Humira® |
AbbVie Pty Ltd |
|
Jul 2018 |
|
| ADALIMUMAB |
Amgevita® |
Amgen Australia Pty Limited |
|
Jul 2018 |
|
| ADALIMUMAB |
Hadlima® |
Merck Sharp & Dohme (Australia) Pty Ltd |
|
Jul 2018 |
|
| ADALIMUMAB UPADACITINIB |
Humira®Rinvoq® |
AbbVie Pty Ltd |
All adalimumab indications except juvenile idiopathic arthritis.Severe active rheumatoid
arthritis. |
Nov 2022 |
|
| ADAPALENE WITH BENZOYL PEROXIDE |
Epiduo® |
Galderma Australia Pty Ltd |
|
Nov 2010 |
|
| ADEFOVIR DIPIVOXIL |
Hepsera® |
- Gilead Sciences Pty Limited
- Australian Liver Association
|
|
Nov 2007 |
|
| ADEFOVIR DIPIVOXIL |
Hepsera® |
Gilead Sciences Pty Limited |
|
Mar 2007 |
|
| ADEFOVIR DIPIVOXIL |
Hepsera® |
Gilead Sciences Pty Limited |
|
Nov 2006 |
|
| ADEFOVIR DIPIVOXIL |
Hepsera® |
Gilead Sciences Pty Limited |
|
Jul 2006 |
|
| ADRENALINE |
|
Alphapharm Pty Ltd |
|
Mar 2016 |
|
| ADRENALINE |
Adrenaline Auto Inject Sun-JV® |
Ranbaxy Australia Pty Limited |
|
Jul 2016 |
|
| ADRENALINE |
Anapen® |
Allergy Concepts Pty Ltd |
Acute allergic reaction with anaphylaxis |
Nov 2020 |
|
| ADRENALINE |
AdrenaJect® |
Sun Pharma ANZ Pty Ltd |
|
Mar 2018 |
|
| ADRENALINE |
Emerade® |
Link Medical Products Pty Ltd |
|
Mar 2018 |
|
| ADRENALINE (EPINEPHRINE) |
|
HEALTH TECHNOLOGY ANALYSTS PTY LIMITED |
Acute allergic reaction with anaphylaxis |
Jul 2024 |
|
| AFATINIB |
Giotrif® |
Boehringer Ingelheim Pty Ltd |
|
Jul 2013 |
|
| AFATINIB |
Giotrif® |
Boehringer Ingelheim Pty Ltd |
|
Jul 2013 |
|
| AFATINIB DIMALEATE |
Giotrif® |
Boehringer Ingelheim Pty Ltd |
|
Jul 2015 |
|
| AFLIBERCEPT |
Eydenzelt® |
CELLTRION HEALTHCARE AUSTRALIA PTY LTD |
Subfoveal choroidal neovascularisation (CNV) due to pathologic myopia (PM) |
Nov 2025 |
|
| AFLIBERCEPT |
Zaltrap® |
sanofi-aventis Australia Pty Ltd |
|
Jul 2013 |
|
| AFLIBERCEPT |
Eylea® |
Bayer Australia Ltd |
|
Jul 2013 |
|
| AFLIBERCEPT |
Eylea® |
Bayer Australia Ltd |
Subfoveal choroidal neovascularisation |
Jul 2019 |
|
| AFLIBERCEPT |
Eylea® |
Bayer Australia Ltd |
|
Nov 2014 |
|